Par Pharmaceuticals is a pharmaceutical company headquartered in Chestnut Ridge, New York, United States. Founded in 1978, the company has become a leading provider of generic pharmaceuticals and focuses on developing, manufacturing, and distributing a wide range of pharmaceutical products. Par Pharmaceuticals offers a diverse portfolio of products, including solid oral dosages, controlled-release medications, injectable drugs, and topical preparations.

The company also specializes in developing and producing complex and niche products, addressing a range of therapeutic areas such as cardiovascular, dermatology, central nervous system, and oncology. On a global scale, Par Pharmaceuticals operates in multiple countries and has a strong presence in the international market. The company has several subsidiaries and partnerships that help expand its reach and distribution capabilities.

For instance, Par Pharmaceuticals has alliances with global pharmaceutical companies for the development, manufacturing, and commercialization of products in select territories. In terms of market position, Par Pharmaceuticals has established itself as a reputable player in the generic pharmaceutical industry. With a wide product portfolio and a focus on quality and affordability, Par Pharmaceuticals competes effectively with other generics manufacturers.

The company has a significant presence in the United States and is well-regarded for its high-quality generic alternatives to brand-name drugs. Throughout its history, Par Pharmaceuticals has achieved notable milestones. In 2012, the company was acquired by Endo International, a global specialty pharmaceutical company, which further strengthened Par Pharmaceuticals' position in the market.

The acquisition facilitated the expansion of its product pipeline and enhanced its research and development capabilities. As of the latest available information, Par Pharmaceuticals continues to operate under the ownership of Endo International. The company remains committed to developing and launching new products and leveraging its global presence to deliver affordable and high-quality healthcare solutions.

However, specific information regarding recent updates or key information about the company's current status is not available at this time